Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration

Title: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration
Author(s): Kantor, R
Katzenstein, DA
Efron, B
Carvalho, AP
Wynhoven, B
Cane, P
Clarke, J
Sirivichayakul, S
Soares, MA
Snoeck, J
Pillay, C
Rudich, H
Rodrigues, R
Holguin, A
Ariyoshi, K
Bouzas, MB
Cahn, P
Sugiura, W
Soriano, V
Brigido, LF
Grossman, Z
Morris, L
Vandamme, AM
Tanuri, A
Phanuphak, P
Weber, JN
Pillay, D
Harrigan, PR
Camacho, R
Schapiro, JM
Shafer, RW
Item Type: Journal Article
Abstract: Background: The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate. Methods and Findings: To assess the impact of HIV-1 subtype and antiretroviral treatment on the distribution of mutations in protease and reverse transcriptase, a binomial response model using subtype and treatment as explanatory variables was used to analyze a large compiled dataset of non- subtype-B HIV-1 sequences. Non-subtyp e-B sequences from 3,686 persons with well characterized antiretroviral treatment histories were analyzed in comparison to subtype B sequences from 4,769 persons. The non-subtype-B sequences included 461 with subtype A, 1,185 with C, 331 with D, 245 with F, 293 with G, 513 with CRF01_AE, and 618 with CRF02_AG. Each of the 55 known subtype B drug-resistance mutations occurred in at least one non-B isolate, and 44 (80%) of these mutations were significantly associated with antiretroviral treatment in at least one non-B subtype. Conversely, of 67 mutations found to be associated with antiretroviral therapy in at least one non-B subtype, 61 were also associated with antiretroviral therapy in subtype B isolates. Conclusion: Global surveillance and genotypic assessment of drug resistance should focus primarily on the known subtype B drug-resistance mutations.
Publication Date: 26-Apr-2005
Date of Acceptance: 7-Mar-2005
URI: http://hdl.handle.net/10044/1/50824
DOI: https://dx.doi.org/10.1371/journal.pmed.0020112
ISSN: 1549-1277
Publisher: Public Library of Science (PLoS)
Start Page: 325
End Page: 337
Journal / Book Title: PLoS Medicine
Volume: 2
Issue: 4
Copyright Statement: © 2005 Kantor et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Science & Technology
Life Sciences & Biomedicine
Medicine, General & Internal
General & Internal Medicine
MEDICINE, GENERAL & INTERNAL
IMMUNODEFICIENCY-VIRUS TYPE-1
NON-B SUBTYPES
DRUG-RESISTANCE
MUTATION PATTERNS
COTE-DIVOIRE
CLADE-C
HIV-1-INFECTED ADULTS
V106M MUTATION
SUSCEPTIBILITY
SEQUENCE
Amino Acid Sequence
Anti-Retroviral Agents
DNA Mutational Analysis
Drug Resistance, Viral
Global Health
HIV Infections
HIV-1
Humans
Molecular Sequence Data
Peptide Hydrolases
RNA-Directed DNA Polymerase
Humans
HIV-1
HIV Infections
Peptide Hydrolases
RNA-Directed DNA Polymerase
Anti-Retroviral Agents
DNA Mutational Analysis
Drug Resistance, Viral
Amino Acid Sequence
Molecular Sequence Data
Global Health
Science & Technology
Life Sciences & Biomedicine
Medicine, General & Internal
General & Internal Medicine
MEDICINE, GENERAL & INTERNAL
IMMUNODEFICIENCY-VIRUS TYPE-1
NON-B SUBTYPES
DRUG-RESISTANCE
MUTATION PATTERNS
COTE-DIVOIRE
CLADE-C
HIV-1-INFECTED ADULTS
V106M MUTATION
SUSCEPTIBILITY
SEQUENCE
11 Medical And Health Sciences
General & Internal Medicine
Publication Status: Published
Article Number: ARTN e112
Appears in Collections:Department of Medicine
Faculty of Medicine



Items in Spiral are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons